Riley Cote – From NHL Enforcer to Psychedelic Therapy Advocate

Hey guys! Today’s episode is more of a fast rant on the recent press release about MindMed raising ANOTHER $19.5M from Canaccord Genuity Corp, on a deal that is set to close tomorrow, March 9th.
Here, I’m discussing:
1. The number MindMed shares being sold and their respective price;
2.Why is MindMed doing this?
3. Potential short term and long term effects on MMED’s stock price
4. Nasdaq uplisting?
5. Market crash thoughts

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #MMEDNews

Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES

Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202

In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.

In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.

This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.

The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.

Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.

Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.

Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5

Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage

Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Psilocybin #DMT #Psychedelics

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.

Timestamps:

0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #CMPS #PsychedelicTherapy